Cellulosic-based interference domain for an analyte sensor

Abstract

The present invention relates generally to devices for measuring an analyte in a host. More particularly, the present invention relates to devices for measurement of glucose in a host that incorporate a cellulosic-based interference domain.

1 . An implantable device for continuous in vivo measurement of a glucose concentration in a host, the implantable device comprising:
 a sensing region operatively connected to electronic circuitry configured to continuously generate, over a period of at least about 3 days, a signal associated with an in vivo concentration of glucose in a host; and   a membrane located over the sensing region, wherein the membrane comprises a first domain configured to control a flux of glucose and oxygen therethrough, a second domain comprising an enzyme configured to react with glucose, and a third domain configured to substantially reduce a flux of at least one interferent therethrough, wherein the third domain comprises at least one cellulosic derivative;   wherein the implantable device is configured to reduce, while immersed in a solution with an acetaminophen concentration of about 6.5 mg/dL, an equivalent glucose response signal associated with acetaminophen to less than about 30 mg/dL.   
     
     
         2 . The implantable device of  claim 1 , wherein the equivalent glucose response signal associated with acetaminophen is less than about 20 mg/dL. 
     
     
         3 . The implantable device of  claim 1 , wherein the equivalent glucose response signal associated with acetaminophen is less than about 10 mg/dL. 
     
     
         4 . The implantable device of  claim 1 , wherein the implantable device is configured to reduce, while immersed in a solution with an ascorbic acid concentration of about 3.8 mg/dL, an equivalent glucose response signal associated with ascorbic acid to less than about 30 mg/dL. 
     
     
         5 . The implantable device of  claim 4 , wherein the equivalent glucose response signal associated with ascorbic acid to less than about 20 mg/dL. 
     
     
         6 . The implantable device of  claim 4 , wherein the equivalent glucose response signal associated with ascorbic acid to less than about 10 mg/dL. 
     
     
         7 . The implantable device of  claim 4 , wherein the equivalent glucose response signal associated with ascorbic acid is substantially about 0 mg/dL. 
     
     
         8 . The implantable device of Claim, wherein the implantable device is configured to reduce, while immersed in a solution with a uric acid concentration of about 9.5 mg/dL, an equivalent glucose response signal associated with uric acid to less than about 30 mg/dL. 
     
     
         9 . The implantable device of  claim 1 , wherein the third domain comprises cellulose acetate. 
     
     
         10 . The implantable device of  claim 9 , wherein the third domain further comprises cellulose acetate butyrate. 
     
     
         11 . The implantable device of  claim 1 , wherein the first domain is disposed more distally from the sensing region than the second domain. 
     
     
         12 . The implantable device of  claim 11 , wherein the second domain is disposed more distally from the sensing region than the third domain. 
     
     
         13 . The implantable device of  claim 1 , wherein the third domain comprises crosslinked polymers. 
     
     
         14 . The implantable device of  claim 1 , wherein the first domain comprises a hydrophobic-hydrophilic copolymer. 
     
     
         15 . The implantable device of  claim 1 , wherein the first domain comprises a fluorocarbon-based material. 
     
     
         16 . The implantable device of  claim 1 , wherein the first domain comprises a copolymer comprising a polyurethane segment and a silicone segment. 
     
     
         17 . The implantable device of  claim 1 , wherein the implantable device is configured to be implanted subcutaneously. 
     
     
         18 . The implantable device of  claim 1 , wherein the implantable device is configured to be implanted transdermally. 
     
     
         19 . The implantable device of  claim 1 , wherein the implantable device is configured to be implanted intravascularly. 
     
     
         20 . The implantable device of  claim 1 , wherein the period of at least about 3 days is a period of at least about 5 days. 
     
     
         21 . The implantable device of  claim 1 , wherein the period of at least about 3 days is a period of at least about 7 days. 
     
     
         22 . The implantable device of  claim 1 , wherein the period of at least about 3 days is a period of at least about 10 days.